capsomer vaccines protect mice from vaginal challenge with human papillomavirus衣壳体与人类乳头瘤病毒疫苗保护小鼠免受阴道挑战.pdfVIP

Capsomer Vaccines Protect Mice from Vaginal Challenge with Human Papillomavirus 1 2 1 1 1 Wai-Hong Wu , Elizabeth Gersch , Kihyuck Kwak , Subhashini Jagu , Balasubramanyam Karanam , 3 2 1,4,5 Warner K. Huh , Robert L. Garcea , Richard B. S. Roden * 1 Department of Pathology, Johns Hopkins University, Baltimore, Maryland, United States of America, 2 Department of Molecular, Cellular and Developmental Biology, University of Colorado, Boulder, Colorado, United States of America, 3 Department of Gynecologic Oncology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America, 4 Department of Oncology, Johns Hopkins University, Baltimore, Maryland, United States of America, 5 Department of Gynecology and Obstetrics, Johns Hopkins University, Baltimore, Maryland, United States of America Abstract Capsomers were produced in bacteria as glutathione-S-transferase (GST) fusion proteins with human papillomavirus type 16 L1 lacking the first nine and final 29 residues (GST-HPV16L1D) alone or linked with residues 13–47 of HPV18, HPV31 and HPV45 L2 in tandem (GST-HPV16L1D-L2x3). Subcutaneous immunization of mice with GST-HPV16L1D or GST-HPV16L1D- L2x3 in alum and monophosphoryl lipid A induced similarly high titers of HPV16 neutralizing antibodies. GST-HPV16L1D- L2x3 also elicited moderate L2-specific antibody titers. Intravaginal challenge studies showed that immunization of mice with GST-HPV16 L1D or GST-HPV16L1D-L2x3 capsomers, like CervarixH, provided complete protection against